Other outcomes
Depression, psychiatric, Anxiety
CORNEA
At baseline, we will perform a cornea confocal examination to quantify the C-fibers of the cornea [Patients will be queried as follows prior, during or after the treatment period:
At screening: the MINI plus, a neuropsychiatric questionnaire aimed to detect active psychiatric problems. This questionnaire will be taken at screening. In case of issues the patient will be referred to his/her family doctor.During the bi-weekly visit to the coordinating center during the course of treatment:A score for opioid and/or cannabis craving (depending on the treatment).Hospital Anxiety and Depression Scale (HADS) questionnaire.The Current Opioid Misuse Measure (COMM) questionnaire.During follow-up (i.e., after the 6-week treatment) bi-weekly:The OOS (“objective withdrawal scale”) questionnaire.The SOS (“subjective withdrawal scale”) questionnaire.A score for opioid or cannabis craving (depending on the treatment).Hospital Anxiety and Depression Scale (HADS) questionnaire.The Current Opioid Misuse Measure (COMM) questionnaire.And finally, at screening, end of treatment, and end of study, the MATE-Q, which gives an indication of drug use [